Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 15/20 | 0.49 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23021441 | 0.87 | RORC (0.48) | RORCNAMPTNR1I2CYP2C9CYP2C19 | |
| SCHEMBL23021424 | 0.86 | RORC (0.49) | RORCNAMPTNR1I2CACNA1GCACNA1H | |
| SCHEMBL20282937 | 0.85 | NAMPT (0.44) | RORCNAMPTNR1I2CYP2D6CYP2C9 | |
| SCHEMBL20282907 | 0.84 | RORC (0.56) | RORCNAMPTNR1I2CYP2D6CYP2C9 | |
| SCHEMBL21783697 | 0.79 | RORC (0.51) | RORCNAMPTNR1I2 | |
| SCHEMBL20282888 | 0.78 | RORC (0.45) | RORCNAMPTNR1I2 | |
| SCHEMBL21783621 | 0.78 | RORC (0.49) | RORCNAMPTNR1I2CYP2D6CYP2C9 | |
| SCHEMBL20282922 | 0.78 | RORC (0.49) | RORCNAMPTNR1I2CYP2D6CYP2C9 | |
| SCHEMBL20283006 | 0.78 | RORC (0.51) | RORCNR1I2CYP2C9CYP2C19 | |
| SCHEMBL20283027 | 0.78 | RORC (0.47) | RORCNAMPTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954215-B2 | Compounds as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-23 | — | — | US | disclosed |
| EP-3555065-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-20200071298-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954215-B2 | Compounds as modulators of ROR gamma | RORB, RORC, RORA | RORC 2/4885NAMPT 1562/4885NR1I2 8/4885 |
| US-20200071298-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORC, RORB, RORA | RORC 1/4885NAMPT 1203/4885NR1I2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.